touchINFECTIOUSDISEASES caught up with Craig Hoesley (University of Alabama School of Medicine, Birmingham, AL, US) to discuss research into intrarectal microbicides for HIV prevention.
Part 2 of our discussion can be viewed here.
The abstract entitled: ‘A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)’ (OA16.05) was presented at the HIVR4P Virtual Conference 2021, 03 February 2021.
Questions:
- What are the current unmet needs in HIV prevention? (0:11)
- Could you give us a brief overview of the history and current status of intrarectal microbicides for HIV prevention? (1:25)
- What will be the likely impact of increased use of intrarectal microbicides on public health? (2:40)
Disclosures: Craig Hoesley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of HIVR4P Virtual Conference 2021.
